Catalyst Biosciences Inc. Common Stock is a biopharmaceutical company focused on developing therapies for hemophilia and other bleeding disorders. They utilize a unique protease engineering platform to create potent and specific coagulation factors that can address the underlying cause of these diseases. With a strong pipeline of product candidates, Catalyst Biosciences aims to improve the lives of patients globally.
Notification